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Abstract 
Purpose: To determine the expression of protein tyrosine phosphatase-1B (PTP-1B) and insulin 
receptor substrate-2 (IRS-2) in the liver tissue of obesity-induced insulin-resistant rats. 
Methods: Insulin resistance (IR) was induced in Wistar rats by placing them on a high fat diet for 6 
weeks, and ursolic acid (UA) was administered. Metformin served as positive control drug. The rats 
were divided into 5 groups based on the treatments given: normal group, positive control group, 
metformin group, high-dose UA group, and low-dose UA group. The general conditions of the rats were 
assessed 4 and 8 weeks after the various treatments. Liver glycogen levels were measured, and liver 
histological examination carried out after tissue processing and staining with hematoxylin and eosin (H 
& E). Real-time polymerase chain reaction (RT-PCR) was employed for the determination of hepatic 
expressions of PTP-1B and IRS-2 mRNAs, while expressions of PTP-1B protein and IRS-2 protein, and 
phosphorylation of IRS-2 tyrosine were assayed by Western blotting.  
Results: Liver glycogen levels were significantly increased in the UA-treated groups (p < 0.05). 
Moreover, UA provoked reductions in the expression of PTP-1B protein (p < 0.05), but up-regulated the 
expression of IRS-2 protein (p < 0.05), and enhanced IRS-2 tyrosine phosphorylation (p < 0.05). 
Conclusion: These results suggest that UA mitigates IR through blockage of PTP-1B expression and 
up-regulation of the expression of IRS-2 mRNA. Therefore, PTP-1B is a potential target for the 
treatment of type 2 diabetes.  
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Obesity is a risk factor for IR through endocrine, 
adipocytokine, inflammatory response and 
intracellular signaling pathways [1]. The liver is 
the main target organ for insulin action in the 
regulation of glycogen synthesis and 
glycogenolysis [2,3]. Insulin receptor substrate-2 
(IRS-2) of the insulin signal cascade is closely 
related to hepatocyte insulin sensitivity [4]. The 
main physiological signal transduction pathway 
of insulin in the liver is IRS-2/phosphatidylinositol 
3-kinase (PI-3K) [5]. Decreases in expressions of 
IRS-2 gene and disorders in phosphorylation 
affect the downstream signal delivery of PI-3K 
protein kinase B (Akt), leading to IR. A member 
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of the protein tyrosine phosphatase (PTP) family, 
protein tyrosine phosphatase-1B (PTP-1B) 
regulates intracellular substrates and tyrosine 
phosphorylation in conjunction with other 
members of the PTP family and protein tyrosine 
kinases, thereby inactivating signal molecules 
such as insulin receptor InsR) and insulin 
receptor substrate (IRs). Thus, PTP-1B regulates 
insulin signal transduction through blockage of 
the insulin signal cascade [6].  
 
Ursolic acid (UA) is a triterpenoid compound 
present in natural plants, and one of the bioactive 
phytochemical components of Chinese traditional 
medicines used for treating diabetes. It inhibits 
transcription of genes related to 
phosphoenolpyruvate shuttle in hepatic 
gluconeogenesis, prevents β-cell apoptosis and 
enhances β-cell function [7,8]. In addition, UA 
enhances the phosphorylation of insulin-
mediated insulin receptor, protein kinase-B and 
glycogen synthase kinase-3, and also enhances 
the transposition of insulin-to-glucose 
transporter-4 (GLUT4) in adipocytes [9,10]. 
 
Metformin is a biguanide hypoglycemic agent 
which increases peripheral tissue glucose uptake 
and sensitivity to insulin while reducing 
peripheral tissue IR. Several investigations have 
reported the effect of UA on different tissues 
such as adipocytes, muscle, blood, L6 myotubes, 
and kidney [8,11-15]. However, the effect of UA 
on obesity-induced IR in the liver has not 
received much attention. 
 
It has been demonstrated that the improvement 
of IR by UA is comparable to that of metformin. 
In the present study, the effect of UA on high fat 
diet-induced IR was investigated in a rat model 
by determination of hepatic expressions of PTP-
1B and IRS-2, and tyrosine phosphorylation in 
IRS-2, so as to provide experimental evidence 





Drugs and reagents 
 
Biosynthetic human insulin was product of 
Danish Novo Nordisk; UA was purchased from 
Shanghai Honghu Trade Co. Ltd, while 
metformin hydrochloride tablets were bought 
from Shanghai Xinyi Pharmacy. Trizol kit and 
Trizol reagent kits were products of Invitrogen, 
USA. Rabbit Anti-human PTP-1B cloning 
antibody, rabbit anti-human IRS-2 polyclonal 
antibody and IRS-2 phosphorylated tyrosine 
antibody were purchased from Abcam. Primer 
was obtained from Dawei Biotechnology Co., Ltd. 
Brightening agent was from E Healthcare; 
electrophoresis buffer and acrylamide were 
products of Shanghai Biyun Biotechnology Co., 
Ltd.), and RIPA buffer was purchased from 
Shanghai Biyun Days Biological Technology Co., 




The present study received approval (approval 
no. 20180101) from the Ethical Committee of 
Department of Pharmacy of Jilin University 
Stomatological Hospital, and was carried out in 
compliance with Helsinki Declaration of 1964 as 
amended in 1996 [16]. 
 
Rat groups and treatments 
 
Healthy male Wistar rats (n = 120, 8 weeks of 
age, body weight 180 ~ 200 g) were provided by 
Shanghai Slack Experimental Animal Co., Ltd 
(certificate no. SYXK-2007-0003). A total of 24 
rats were assigned to the normal group, while the 
remaining 96 rats comprised the positive control 
group and treatment groups (UA groups and 
metformin group). The normal group received 
basic diet provided by Animal Center of the 
Second Military Medical University. The other 
groups (n = 24 each) were given a high fat diet 
(consisting of basic diet, 10 % lard oil, 1 % 
cholesterol, 10 % yolk powder and 0.1 % bile 
salt) provided by Shanghai Slack Experimental 
Animal Co., Ltd. The rats were fed the high fat 
diet for 6 consecutive weeks to produce obesity-
induced IR model. After 6 weeks, rats in UA 
groups were randomly divided into low and high-
dose UA groups (24 rats each) and treated with 
high fat diet containing 0.14 % and 0.27 % UA, 
respectively. The metformin group was given 50 
mg metformin/kg/day [11,15]. 
 
Morphological examination of liver tissues 
 
Liver tissues were processed for light 
microscopy, and sectioned and stained with 
H&E. The stained sections were examined under 
the light microscope for pathological changes 
such as steatosis, fibrosis and inflammation. 
 
Determination of liver PTP-1B and IRS-2 
mRNA 
 
Liver PTP-1B and IRS-2 mRNAs were 
determined by RT-PCR. Total RNA extraction 
from liver tissue was carried out using TRizol 
reagent in line with kit instructions. Forward and 
reverse primers were provided by Shanghai 
Daweike Company. The forward and reverse 
primers for PTP-1B were:  
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Forward: 5'-αCC CTG TGC GGA AAT GCGGG-
3' 
Reverse: 5'-GGC AGT CAG TCA ACC CCG GC-
3'.  
 
For IRS-2, the forward and reverse primers were: 
 
Forward: 5'-TGC GAA CAG CCG TCG GTG AC-
3'  
Reverse: 5'-GAC CGG TGA CGG CTG AAC 
GG-3'.  
 
The forward and reverse primers for GAPDH 
were: 
 
Forward: 5'-αGA ACA TCA TCC CTG CAT CC-3'  
Reverse: 5'-TGG ATA CAT TGG GGG TAG GA-
3'.  
 
Real-time fluorescence quantitative PCR was 
performed after reverse transcription. The 
relative concentrations of PTP-1B, IRS-2 and 
GAPDH mRNAs were obtained from the 
standard curve. The expression of GAPDH was 
reflected by the ratio of relative concentration of 
PTP-1B, IRS-2 and GAPDH. Relative expression 
(RE) of mRNA calculated as in Eq 1. 
 
REmRNA = 2-ΔCT×100 …………… (1)  
 
where ΔCT = (CT value of target gene) – (CT 
value of internal reference GAPDH). 
 
Expression of PTP-1B and IRS-2 protein and 
IRS-2 tyrosine phosphorylation levels 
 
After conventional methods of extraction of tissue 
proteins, polypropylene phthalamide gel 
electrophoresis and brightening agent were used 





Data are expressed as mean ± SD, and 
Student’s t-test was used to compare between 
groups. SPSS 19.0 software was employed for 
statistical analysis. Statistical significance was 






In line with homeostasis model, assessment 
insulin resistance (HOMO-IR) index for 
assessment of IR, the HOMA-IR index of the 
high-fat diet group (0.82 ± 0.22) was significantly 
higher than that of normal diet group (0.65 ± 
0.11, t = 3.20, p = 0.00; Figure 2) [17,18]. This 
demonstrates that insulin sensitivity was 
significantly decreased and that IR was 
successfully established after 6 weeks of 
exposure to high fat diet. 
 
Physical condition of the rats 
 
In the normal group, the rats had good mental 
state, normal appetite and clear skin. On the 
other hand, rats in treatment group were 
lethargic and docile, and had dull skin. 
 
Liver glycogen levels 
 
The levels of glycogen in the UA-treated groups 
were significantly higher than corresponding level 
in the normal control group (p < 0.05, p < 0.01). 
The level of glycogen in high-dose UA group at 
week 8 was significantly higher than that of the 
metformin group (p < 0.01). These results are 
shown in Table 1. 
 
Table 1: Effect of various treatments on liver glycogen 
levels (mean ± SD) 
 
Group Week n Liver glycogen level 
Normal 4 12 32.44 ± 6.81 8 12 36.63 ± 2.98 
Positive control 4 12 7.05 ± 2.52
** 
8 12 6.95 ± 2.60** 
Metformin 4 12 12.89 ± 2.71
**Δ 
8 10 12.46 ± 1.73**ΔΔ 
High-dose UA 4 12 17.91 ± 2.80
*ΔΔ 
8 12 17.32 ± 2.61**ΔΔ▲▲ 
Low-dose UA 4 12 15.38 ± 2.63
*ΔΔ 
8 12 15.14 ± 2.43**ΔΔ 
*P < 0.05 and **p < 0.01, compared to normal group; Δp 
< 0.05 and ΔΔp < 0.01, compared to positive control 





There was no significant abnormality in the 
morphology of liver tissue in the normal group. In 
contrast, rats in the model group showed severe 
fatty degeneration and vacuoles in hepatocytes. 
Part of the liver cells showed diffuse necrosis, 
infiltration of inflammatory cells and slight 
fibrosis.  
 
Treatment with UA produced some 
improvements in liver pathology, as evident in 
mild-to-moderate steatosis, decreased steatosis 
cells, normal hepatocellular morphology, 
decreased cytoplasmic lipid droplets, clear 
cytoplasm, absence of inflammatory cell 
infiltration and absence of fibrosis (Figure 1 and 
Figure 2). 
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Figure 1: Liver morphology at week 4. (a) Normal 
group; (b) Positive control group; (c) Metformin group; 
(d) High-dose UA group; (e) low-dose UA group 
 
 
Figure 2: Liver morphology at week 8. (a) Normal 
group; (b) positive control group; (c) Metformin group; 
(d) High-dose UA group; (e) Low-dose UA group 
 
Expression of PTP-1 and IRS-2 mRNA in liver 
tissue 
 
Normal group had high expression of IRS-2 
mRNA and low expression of PTP-1 mRNA, 
while positive control group had low expression 
of IRS-2 mRNA and high expression of PTP-1 
mRNA. Thus, UA and metformin treatments 
increased the expressions of IRS-2 mRNA and 
reduced the expression of PTP-1B mRNA (p < 
0.01, p < 0.05). These results are shown in Table 
2. 
 
Expression of PTP-1B and IRS-2 protein in rat 
liver 
 
The results of western blot showed that the 
expression of PTP-1B protein in liver tissue of 
the positive control group was higher than that in 
normal control group, while the expression of 
IRS-2 protein was lower. However, after 4 and 8 
weeks of UA exposure, the expression of PTP-
1B protein decreased while the expression of 
IRS-2 protein increased in the UA-treated 
groups. The effects produced by metformin were 
similar to those of UA (Figure 3 and Figure 4). 
 
Table 2: Effect of UA and metformin on the 
expressions of PTP-1 and IRS-2 mRNA in liver tissue 
(mean ± SD, n = 8) 
 
Group Week PTP-1B mRNA (100×2-ΔCT) 
IRS-2 mRNA 
(100×2-ΔCT) 
Normal 4 0.22 ± 0.02 7.07 ± 0.78 8 0.38 ± 0.11 7.74 ± 0.75 
Positive 
control 
4 4.17 ± 0.89** 0.40 ± 0.07** 
8 2.80 ± 0.53** 0.30 ± 0.03** 
Metformin 4 1.88 ± 0.57
**ΔΔ 1.13 ± 0.21**Δ 
8 0.62 ± 0.05ΔΔ 1.88 ± 0.36**ΔΔ 
High-dose 
UA 
4 0.85 ± 0.17ΔΔ▲ 0.96 ± 0.16** 
8 1.69±0.35*ΔΔ▲▲ 1.92 ± 0.47**ΔΔ 
Low-dose 
UA 
4 1.44 ± 0.41**ΔΔ 0.90 ± 0.19** 
8 0.82 ± 0.20ΔΔ## 2.32 ± 0.48**ΔΔ 
*p < 0.05 and **p < 0.01, compared to normal group; Δp 
< 0.05 and ΔΔp < 0.01, compared to control group; ▲p 
< 0.05 and ▲▲p < 0.01, compared to metformin group; 




Figure 3: Effects of UA and metformin on the 
expressions of PTP-1B and IRS-2 proteins in rat liver 
at week 4 (n = 8) 
 
 
Figure 4: Effects of UA and metformin on the 
expressions of PTP-1B and IRS-2 protein in rat liver at 
week 8 (n = 8) 
 
IRS-2 tyrosine phosphorylation in rat liver 
 
The results of western blot showed that IRS-2 
tyrosine phosphorylation in liver tissue of rats in 
the control group was significantly lower than that 
of normal group. However, after 4 and 8 weeks 
of UA treatment, the phosphorylation of IRS-2 
tyrosine increased. A similar effect was produced 
by metformin (Figure 5 and Figure 6). 
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Figure 5: Effect of UA and metformin on IRS-2 




Figure 6: Effect of UA and metformin on IRS-2 




The main features of IR are significant 
impairment of glucose metabolism and 
associated abnormal lipid metabolism. Insulin 
resistance increases gluconeogenesis and 
glycogen degradation, and decreases glycogen 
synthesis. At the same time, disorders in lipid 
metabolism result in excessive accumulation of 
fat in the liver parenchymal cells, ultimately 
leading to the occurrence of fatty liver [19]. 
Ursolic acid improves glucose tolerance and 
dyslipidemia [20]. Insulin tolerance test has 
shown that UA improves sensitivity to insulin, 
resulting in enhanced liver glycogen synthesis 
and mitigation of liver steatosis. 
 
Insulin resistance is due to impairment of signal 
transduction to insulin receptor, which at the 
molecular level, involves IRS. This results in 
reduction in IRS gene expression, reduction in 
protein content, and dysfunction in insulin 
signaling. It is known that IRS-2 is present in the 
liver and islet β cells where it regulates lipid 
synthesis through steroid regulatory element 
binding protein (SREBP). Down-regulation of 
IRS-2 affects the downstream signaling of 
PI3K/Akt, resulting in reduced hepatic glycogen 
synthesis and increased fat synthesis [21]. In the 
present study, IRS-2 mRNA and related protein 
expressions, and tyrosine phosphorylation in the 
liver of insulin-resistant rats were determined by 
molecular biology methods. The results obtained 
showed that the expressions of IRS-2 mRNA and 
its related proteins were significantly increased 
by UA, relative to the high fat diet-induced IR 
group (positive control). This finding suggests 
that reduced expression of IRS-2 may lead to IR. 
 
PTP-1B interacts with the receptor for insulin as 
well as IRS. These interactions reduce the 
degree of tyrosine phosphorylation in these 
regulatory proteins, thereby blocking the insulin 
signal cascade. Reduction of the expression of 
PTP-1B in the liver and muscle of the diabetic 
animal model increases the level of tyrosine 
phosphorylation of insulin receptor and its 
substrate, which enhances insulin signaling and 
response [22]. In the present study, RT-PCR and 
Western blotting were applied in determining 
PTP-1B mRNA and its protein expressions in the 
liver of IR rats. Treatment with UA led to 
significantly lower expression of PTP-1B than in 
the untreated IR group. This indicates that the 
expression of PTP-1B may be one of the key 
molecular factors linked to insulin signal 




The results obtained in this study suggest that 
UA mitigates IR by inhibiting the expression of 
PTP-1B and up-regulating the expression of IRS-
2 mRNA. Thus, PTP-1B is a potential target for 
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